Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells

Hepatology

Volumn 36, Issue 4 I, 2002, Pages 885-894

  Kern, Michael André ^a   Schubert, Dominic ^a   Sahi, Dina ^a   Schöneweiß, Mirja Mareike ^a   Moll, Ilona ^a   Haugg, Anke Maria ^a   Dienes, Hans Peter ^a   Breuhahn, Kai ^a   Schirmacher, Peter ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BROXURIDINE; CASPASE 3; CASPASE 6; CASPASE 9; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; MELOXICAM; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; SULINDAC SULFIDE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRAIN HEPG2; CELL STRUCTURE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVATION; ENZYME ANALYSIS; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; NICK END LABELING; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-ASSOCIATED DEATH PROTEIN; CARCINOMA, HEPATOCELLULAR; CARRIER PROTEINS; CASPASES; CELL DIVISION; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; ISOENZYMES; LIVER NEOPLASMS; MEMBRANE PROTEINS; PHOSPHORYLATION; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZOLES; SULFONAMIDES; THIAZINES; THIAZOLES; TUMOR CELLS, CULTURED;

EID: 0036788542     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0270-9139(02)00094-0     Document Type: Article

References (51)

1. Harris CC, Sun T. Multifactoral etiology of human liver cancer. Carcinogenesis 1984;5:697-701.
2. Kondo M, Yamamoto H, Nagano H, Okamij, Ito Y, Shimizu J, Eguchi H, et al. Increased expression of COX-2 in nontumot liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. Clin Cancer Res 1999;5:4005-4012.
3. Taketo MM. COX-2 and colon cancer. Inflamm Res 1998;47(Suppl 2): S112-116.
4. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 1998;90:1529-1536.
5. Ziegler J. Cancer and arthritis share underlying processes. J Natl Cancer Inst 1998;90:802-803.
6. Eberhart CE, Dubois RN. Eicosanoids and the gastrointestinal tract. Gastroenterology 1995;109:285-301.
7. O'Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 1993;330:156-160.
8. Fosslien E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci 2000;37:431-502.
9. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-l and -2. J Biol Chem 1996;271:33157-33160.
10. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE. Cyclooxygenase in biology and disease. FASEB J 1998;12:1063-1073.
11. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998;38:97-120.
12. Tsujii M, Kawano, S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-716.
13. Charpigny G, Reinaud P, TambyJP, Creminon C, Guillomot M. Cyclooxygenase-2 unlike cyclooxygenase-1 is highly expressed in ovine embryos during the implantation period. Biol Reprod 1997;57:1032-1040.
14. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 2000;30:3-21.
15. Labayle D, Fischer D, Vielh P, Drouhin F, Pariente A, Bories C, Duhamel O, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991;101:635-639.
16. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, et al., Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803-809.
17. Taketo MM. Cycl0oxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst 1998;90:1609-1620.
18. Vane JR, Mitchell JA, Appleton I, Tomlinson A, Bishop-Bailey D, Croxtall J, Willoughby DA. Inducible isoforms of cyclooxygenase and nitricoxide synthase in inflammation. Proc Natl Acad Sci U S A 1994;91:2046-2050.
19. Vane J. Towards a better aspirin. Nature 1994;367:215-216.
20. DuBois RN, Awad J, Morrow J, Roberts LJ, Bishop PR. Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-alpha and phorbol ester. J Clin Invest 1994;93:493-498.
21. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TISIO, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991;266:12866-12872.
22. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501.
23. Hara A, Yoshimi N, Niwa M, Ino N, Mori H. Apoptosis induced by NS-398, a selective cyclooxygenase-2 inhibitor, in human colorectal cancer cell lines. Jpn J Cancer Res 1997;88:600-604.
24. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells, Cancer Res 1998;58:362-366.
25. Erickson BA, Longo WE, Panesar N, Mazuski JE, Kaminski DL. The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis. J Surg Res 1999;81:101-107.
26. Liu XH, Yao S, Kirschenbaum A, Levine AC. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 1998;58:4245-4249.
27. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS. The cyclooxygenase-2 inhibitot celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000;275:11397-11403.
28. Sawaoka H, Kawano S, Tsuji S, Tsujii M, Gunawan ES, Takei Y, Nagano K, et al. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Physiol 1998;274:G1061-1067.
29. Chan TA, Morin PJ, Vogelstein B, Kinzier KW. Mechanisms underlying nonsteroidal antiinfiammatory drug-mediated apoptosis, Proc Nad Acad Sci U S A 1998;95:681-686.
30. Shiota G, Okubo M, Noumi T, Noguchi N, Oyama K, Takano, Y, Yashima K, et al. Cyclooxygenase@-2 expression in hepatocellular carcinoma. Hepatogastroenterology 1999;46:407-412.
31. Koga H, Sakisaka S, Ohishi M, Kawaguchi T, Taniguchi E, Sasatomi K, Harada M, et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology 1999;29, 688-696.
32. Bae SH, Jung ES, Park YM, Kim BS, Kim BK, Kim DG, Ryu WS., Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398, Clin Cancer Res 2001;7:1410-1418.
33. Church GM, Gilbert W. Genomic sequencing. Proc Natl Acad Sci U S A 1984;81:1991-1995.
34. Herschman HR. Prostaglandin synthase 2. Biochim Biophys Acta 1996;1299:125-140.
35. Marchio A, Meddeb M, Pineau P, Danglot G, Tiollais P, Bernheim A, Dejean A. Recurrent chromosomal abnormalities in hepatocellular carcinoma detected by comparative genomic hybridization. Genes Chromosomes Cancer 1997;18:59-65.
36. Niketeghad F, Decker HJ, Caselmann WH, Lund P, Geissler F, Dienes HP, Schirmacher P. Frequent genomic imbalances suggest commonly altered turnout genes in human hepatocarcinogenesis. Br J Cancer 2001;85:697-704.
37. Tay A, Simon JS, Squire J, Hamel K, Jacob HJ, Skorecki K. Cytosolic phospholipase A2 gene in human and rat: chromosomal localization and polymorphic markers. Genomics 1995;26:138-141.
38. Kudo I, Murakami M. Diverse functional coupling of prostanoid biosynthetic enzymes in various cell types. Adv Exp Med Biol 1999;469:29-35.
39. Di Popolo A, Memoli A, Apicella A, Tuccillo C, di Palma A, Ricchi P, Acquaviva AM, et al. IGF-II/IGF-I receptor pathway up-regulates COX-2 mRNA expression and PGE2 synthesis in Caco-2 human colon carcinoma cells. Oncogene 2000;19:5517-5524.
40. Sheng GG, Shao J, Sheng H, Hooton EB, Isakson PC, Morrow JD, Coffey RJ, et al. A selective cyclooxygenase 2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells. Gastroenterology 1997;113:1883-1891.
41. Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastas Rev 2000;19:19-27.
42. Richter M, Weiss M, Weinberger I, Furstenberger G, Marian B. Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors. Carcinogenesis 2001;22:17-25.
43. Shureiqi I, Chen D, Lotan R, Yang P, Newman RA, Fischer SM, Lippman SM. 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res 2000;60:6846-6850.
44. Rahman MA, Dhar DK, Masunaga R, Yamanoi A, Kohno H, Nagasue N. Sulindac and exisulind exhibit a significant antiproliferative effect and induce apoptosis in human hepatocellular carcinoma cell lines. Cancer Res 2000;60:2085-2089.
45. Rudnick DA, Perlmutter DH, Muglia LJ. Prostaglandins are required for CREB activation and cellular proliferation during liver regeneration. Proc Natl Acad Sci U S A 2001;98:8885-8890.
46. Hufnagl K, Parzefall W, Marian B, Kafer M, Bukowska K, Schulte-Hermann R, Grasl-Kraupp B. Role of transforming growth factor alpha and prostaglandins in preferential growth of preneoplastic rat hepatocytes. Carcinogenesis 2001;22:1247-1256.
47. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998;282:1318-1321.
48. Herrmann C, Block C, Geisen C, Haas K, Weber C, Winde G, Moroy T, et al. Sulindac sulfide inhibits Ras signaling. Oncogene 1998;17:1769-1776.
49. Piazza GA, Rahm AK, Finn TS, Fryer BH, Li H, Stoumen AL, Pamukcu R, et al. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction, Cancer Res 1997;57:2452-2459.
50. Lin MT, Lee RC, Yang PC, Ho FM, Kuo ML. Cyclooxygenase-2 inducing a Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells: Involvement of PI 3-K/Akt pathway. J Biol, Chem 2001;3:3.
51. Yamamoto Y, Yin MJ, Lin KM, Gaynor RB. Sulindac inhibits activation of the NF-κB pathway. J Biol Chem 1999;274:27307-27314.